sellWeak cluster of 310b5-1 plan
Hohl Benjamin sold $69k of ELVN
CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc.. 3,250 shares at an average of $21.33, traded Mar 27, 2025, filed Mar 31, 2025.
Warning score
15Value
$69k
3,250 shares
Holdings after
23,000
-12% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-009301, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 27, 2025 | MOption exercise Common Stock10b5-1 | +3,250 | $2.48 | $8,060 | 26,250 | Mar 31, 2025 |
| Mar 27, 2025 | SOpen-market sale Common Stock10b5-1 | -3,250 | $21.33 | $69k | 23,000 | Mar 31, 2025 |
| Mar 27, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,250 | $0.00 | $0 | 128,556 | Mar 31, 2025 |
Related signals
Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 2Weak | sell 310b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $23k | 1,000 | |
| 23Weak | sell 410b5-1 | ELVN Enliven Therapeutics, Inc. | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | $258k | 12,500 | |
| 33Weak | sell 410b5-1 | ELVN Enliven Therapeutics, Inc. | Kintz Samuel PRESIDENT AND CEO | $260k | 12,500 | |
| 26Weak | sell 410b5-1 | ELVN Enliven Therapeutics, Inc. | Patel Anish CHIEF OPERATING OFFICER | $143k | 6,667 | |
| 8Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $66k | 3,250 | |
| 19Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Patel Anish CHIEF OPERATING OFFICER | $146k | 6,667 | |
| 0Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $23k | 1,000 | |
| 8Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $70k | 3,250 | |
| 34Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Patel Anish CHIEF OPERATING OFFICER | $686k | 28,367 | |
| 0Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin CHIEF FINANCIAL OFFICER | $25k | 1,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.